


WHAT IS CLAIMED IS:

1. A compound of Formula I:



5 wherein

a and b are independently 0 or 1;


m is independently 0, 1 or 2;

n is 0, 1, 2, 3, 4, 5, or 6;

10 p is 0, 1, 2, 3, 4, 5, or 6;

s is 0, 1 or 2;

t is 0, 1, 2, or 3;



is aryl or heterocyclyl;

15

R¹ is independently selected from:

- 1) C₁₋₁₀ alkyl,
- 2) C₃₋₆ cycloalkyl,
- 3) C₂₋₁₀ alkenyl,
- 20 4) C₂₋₁₀ alkynyl,
- 5) aryl,
- 6) heterocyclyl,
- 7) OC₁₋₆ alkyl-NR⁵R⁶,
- 8) NO₂,
- 25 9) OR⁶, and
- 10) N(R⁵)₂,

said alkyl, cycloalkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one or more substituents selected from R⁷;

R^{1a} is independently selected from:

- 5 1) H,
- 2) unsubstituted or substituted C₁₋₁₀ alkyl,
- 3) unsubstituted or substituted C₃₋₆ cycloalkyl,
- 4) unsubstituted or substituted aryl, and
- 5) unsubstituted or substituted heterocyclyl;

10

R² is:

- 1) H,
- 2) unsubstituted or substituted C₁₋₆ alkyl,
- 3) C₁₋₃ perfluoroalkyl,
- 15 4) OR⁶, or
- 5) halogen;

R³ is:

- 20 1) H,
- 2) unsubstituted or substituted C₁₋₆ alkyl,
- 3) C₁₋₃ perfluoroalkyl,
- 4) OR⁶, or
- 5) halogen;

25 R^{4a} is:

- 1) NR⁵(CR^{1a2})_nR⁸,
- 2) NR⁵(CR^{1a2})_nOR⁵,
- 3) R⁸S(O)_mR⁸,
- 4) NR⁵(CR^{1a2})_nC(O)NR⁵R⁶,
- 30 5) halo,
- 6) C_{2-C6} alkenyl(CR^{1a2})_nOR⁵,
- 7) C_{2-C6} alkynyl(CR^{1a2})_nOR⁵,
- 8) OR⁵,
- 9) C(O)R⁵,
- 35 10) R⁸,

- 11) $\text{NR}^5(\text{CR}^{1a_2})_n\text{NR}^5\text{R}^6$,
- 12) $\text{R}^8\text{C}(\text{O})\text{NR}^5(\text{CR}^{1a_2})_n\text{NR}^5\text{R}^6$,
- 13) $\text{C}(\text{O})\text{NR}^5(\text{CR}^{1a_2})_n\text{R}^8$,
- 14) $\text{C}(\text{O})\text{OR}^5$,
- 15) $\text{C}(\text{O})\text{NR}^5(\text{CR}^{1a_2})_n\text{NR}^5\text{R}^6$, or
- 16) $\text{C}(\text{O})\text{NR}^5(\text{CR}^{1a_2})_n\text{OR}^5$;

R^{4b} is independently selected from:

- 1) C_{1-10} alkyl,
- 2) C_{3-6} cycloalkyl,
- 3) C_{2-10} alkenyl,
- 4) C_{2-10} alkynyl,
- 5) aryl,
- 6) heterocyclyl,
- 7) OC_{1-6} alkyl- NR^5R^6 ,
- 8) NO_2 ,
- 9) OR^6 , and
- 10) NR^5R^6 ,

said alkyl, cycloalkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one or more substituents selected from R^7 ;

R^5 and R^6 are independently selected from:

- 1) H,
- 2) halo
- 3) aralkyl,
- 4) $(\text{C}=\text{O})\text{O}_b\text{C}_{1-10}$ alkyl,
- 5) $(\text{C}=\text{O})\text{O}_b\text{C}_{3-8}$ cycloalkyl,
- 6) $(\text{C}=\text{O})\text{O}_b$ aryl,
- 7) $(\text{C}=\text{O})\text{O}_b$ heterocyclyl,
- 8) C_{1-10} alkyl,
- 9) aryl,
- 10) C_{2-10} alkenyl,
- 11) C_{2-10} alkynyl,
- 12) heterocyclyl,
- 13) C_{3-8} cycloalkyl,

14) SO_2R^a , and

15) $(\text{C}=\text{O})\text{NR}^b_2$,

said alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^7a , or

5

R^5 and R^6 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^7 ;

10

R^7 is independently selected from:

1) $(\text{C}=\text{O})_a\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl,

2) $(\text{C}=\text{O})_a\text{O}_b$ aryl,

15

3) $\text{C}_2\text{-C}_{10}$ alkenyl,

4) $\text{C}_2\text{-C}_{10}$ alkynyl,

5) $(\text{C}=\text{O})_a\text{O}_b$ heterocyclyl,

6) CO_2R^a ,

7) halo,

20

8) CN,

9) OR^a ,

10) $\text{O}_b\text{C}_1\text{-C}_6$ perfluoroalkyl,

11) $\text{O}_a(\text{C}=\text{O})_b\text{NR}^5\text{R}^6$,

12) oxo,

25

13) $\text{C}(\text{O})\text{R}^a$,

14) $(\text{N}=\text{O})\text{R}^5\text{R}^6$, and

15) $(\text{C}=\text{O})_a\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^7a ;

30

R^7a is independently selected from:

1) $(\text{C}=\text{O})_a\text{O}_b(\text{C}_1\text{-C}_{10})$ alkyl,

2) $\text{O}_a(\text{C}_1\text{-C}_3)$ perfluoroalkyl,

3) $(\text{C}_0\text{-C}_6)$ alkyl- $\text{S}(\text{O})_m\text{R}^a$, wherein m is 0, 1, or 2,

35

4) oxo,

- 5) OR^a,
- 6) halo,
- 7) CN,
- 8) (C₂-C₁₀)alkenyl,
- 9) (C₂-C₁₀)alkynyl,
- 10) (C₃-C₆)cycloalkyl,
- 11) (C₀-C₆)alkyl-aryl,
- 12) (C₀-C₆)alkyl-heterocyclyl,
- 13) (C₀-C₆)alkyl-N(R^b)₂,
- 14) C(O)R^a, and
- 15) (C₀-C₆)alkyl-CO₂H,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, N(R^b)₂, and -N(R^b)-(C₁-C₆)alkyl-N(R^b)₂;

R⁸ is independently selected from:

- 1) C₁-C₁₀ alkyl,
- 2) aryl,
- 3) heterocycle, and
- 4) C₃-C₁₀ cycloalkyl,

said alkyl, aryl, heterocyclyl, and cycloalkyl is optionally substituted with one or more substituents selected from R⁷;

R^a is independently selected from H, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl, and heterocyclyl;

R^b is independently selected from H, (C₁-C₆)alkyl, aryl, heterocyclyl, aralkyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl and S(O)₂R^a

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to Claim 1 wherein

R¹ is independently selected from:

- 1) C₁-6 alkyl,
- 2) C₃-6 cycloalkyl,
- 3) C₁-6 alkoxy,
- 4) aryl,

- 5) heterocyclyl,
- 6) OC₁₋₆ alkyl-NR⁵R⁶, and
- 7) OR⁶;

said alkyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with one to three
5 substituents selected from R⁷;

R² is:

- 1) H,
- 2) C₁₋₆ alkyl, or
- 10 3) OR⁶;

R^{4b} is independently selected from:

- 1) C₁₋₆ alkyl,
- 2) C₃₋₆ cycloalkyl,
- 15 3) aryl,
- 4) heterocyclyl,
- 5) OC₁₋₆ alkyl-NR⁵R⁶,
- 6) OR⁶, and
- 7) NR⁵R⁶,

20 said alkyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with one to three
substituents selected from R⁷

or a pharmaceutically acceptable salt or stereoisomer thereof.

25 3. The compound according to Claim 2 wherein

n is independently 0, 1, 2, 3, or 4;

s is 0 or 1;

t is 0, 1 or 2;

30  A

is phenyl, pyridyl, pyrimidinyl, thienyl, or pyrazinyl;

R³ is:

- 1) H,
- 2) C₁₋₆ alkyl, or

3) Halogen

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. The compound according to Claim 3 wherein

s is 0;

t is 0 or 1;

R¹ is independently selected from

- 1) C₁₋₆ alkyl,
- 2) C₃₋₆ cycloalkyl,
- 3) OC₁₋₆ alkyl-NR⁵R⁶,
- 4) OR⁶, and
- 5) NR⁵R⁶,

said alkyl, alkoxy and cycloalkyl is optionally substituted with one to three substituents selected from R⁷;

R² is H or C₁₋₃ alkyl;

R³ is H or C₁₋₃ alkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A compound selected from:

1-phenyl-N-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]methanamine;

N-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]-N-propylamine;

N-(2-methoxyethyl)-N-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]butan-1-amine;

N-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]cyclopropanamine;

2-methoxy-N-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]ethanamine;

1-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]-N-(pyridin-3-ylmethyl) methanamine;

1-(3-{[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]amino}propyl)pyrrolidin-2-one;

1-(1-benzylpyrrolidin-3-yl)-N-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl] methanamine;

6-(4-{[4-(methylsulfonyl)piperazin-1-yl]methyl}phenyl)-3-phenylpyrazolo[1,5-a] pyrimidine;


1-[3-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]-N-(pyridin-3-ylmethyl) methanamine;

- N-3-[3-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]-beta-alaninamide;
1-phenyl-N-[3-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]methanamine;
N-[3-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)benzyl]-N-propylamine;
6-[4-(3-morpholin-4-ylpropyl)phenyl]-3-phenylpyrazolo[1,5-a]pyrimidine;
5 3-phenyl-6-[4-(3-piperidin-1-ylpropyl)phenyl]pyrazolo[1,5-a]pyrimidine;
N-1-ethyl-N-2-dimethyl-N-1-{3-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]propyl}ethane-1,2-diamine;
N-[2-(dimethylamino)ethyl]-1-{3-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]propyl}-D-prolinamide;
10 N-[2-(dimethylamino)ethyl]-1-{3-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]propyl}-L-prolinamide;
6-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-phenylpyrazolo[1,5-a]pyrimidine;
3-phenyl-6-[4-(piperazin-1-ylcarbonyl)phenyl]pyrazolo[1,5-a]pyrimidine;
4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)-N-pyrrolidin-3-ylbenzamide;
15 6-{4-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]phenyl}-3-phenylpyrazolo[1,5-a]pyrimidine;
6-[4-(3-oxo-3-piperazin-1-ylpropyl)phenyl]-3-phenylpyrazolo[1,5-a]pyrimidine;
3-[4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]-N-pyrrolidin-3-ylpropanamide;
N-[2-(dimethylamino)ethyl]-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
20 4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)-N-(pyridin-3-ylmethyl)thiophene-2-carboxamide;
N-(2-methoxyethyl)-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
N-(3-morpholin-4-ylpropyl)-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
N-[3-(dimethylamino)-2,2-dimethylpropyl]-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
25 N-[2-(diethylamino)ethyl]-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
N-[3-(1H-imidazol-1-yl)propyl]-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)-N-(2-pyridin-3-ylethyl)thiophene-2-carboxamide;
30 N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
N-[(1-ethylpyrrolidin-3-yl)methyl]-4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)thiophene-2-carboxamide;
N-[2-(dimethylamino)ethyl]-6-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)pyridine-2-carboxamide;
35 and

N-(2-aminoethyl)-6-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)pyridine-2-carboxamide;


or a pharmaceutically acceptable salt or stereoisomer thereof.

- 5 6. The compound according to Claim 5 which is
6-[4-(3-morpholin-4-ylpropyl)phenyl]-3-phenylpyrazolo[1,5-a]pyrimidine




or a pharmaceutically acceptable salt or stereoisomer thereof.

- 10 7. The compound according to Claim 5 which is
3-phenyl-6-[4-(3-piperidin-1-ylpropyl)phenyl]pyrazolo[1,5-a]pyrimidine




or a pharmaceutically acceptable salt or stereoisomer thereof.

- 15 8. The compound according to Claim 5 which is
6-{4-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]phenyl}-3-phenylpyrazolo[1,5-a] pyrimidine




or a pharmaceutically acceptable salt or stereoisomer thereof.

9. The compound according to Claim 5 which is
 5 6-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-phenylpyrazolo[1,5-a]pyrimidine



or a pharmaceutically acceptable salt or stereoisomer thereof.

10. The compound according to Claim 5 which is
 6-(4-{[4-(methylsulfonyl)piperazin-1-yl]methyl}phenyl)-3-phenylpyrazolo[1,5-a] pyrimidine



or a pharmaceutically acceptable salt or stereoisomer thereof.

11. A pharmaceutical composition which is comprised of a compound in
 accordance with Claim 1 and a pharmaceutically acceptable carrier.

12. A method of treating or preventing cancer in a mammal in

need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. A method of treating cancer or preventing cancer in accordance with
5 Claim 12 wherein the cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.

14. A method of treating or preventing cancer in accordance with Claim 12
10 wherein the cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, glioblastomas and breast carcinoma.

15. A method of treating or preventing a disease in which angiogenesis is
implicated, which is comprised of administering to a mammal in need of such treatment a
therapeutically effective amount of a compound of Claim 1.

16. A method in accordance with Claim 15 wherein the disease is an ocular
disease.

17. A method of treating or preventing retinal vascularization which is
comprised of administering to a mammal in need of such treatment a therapeutically effective
20 amount of compound of Claim 1.

18. A method of treating or preventing diabetic retinopathy which is
comprised of administering to a mammal in need of such treatment a therapeutically effective
amount of compound of Claim 1.

19. A method of treating or preventing age-related macular degeneration
which is comprised of administering to a mammal in need of such treatment a therapeutically
effective amount of a compound of Claim 1.

20. A method of treating or preventing macular edema which is comprised of
administering to a mammal in need of such treatment a therapeutically effective amount of a
compound of Claim 1.

21. A method of treating or preventing retinal ischemia which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

5 22. A method of treating or preventing inflammatory diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

10 23. A method according to Claim 22 wherein the inflammatory disease is selected from rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.

15 24. A method of treating or preventing a tyrosine kinase-dependent disease or condition which comprises administering a therapeutically effective amount of a compound of Claim 1.

25. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

20 26. A process for making a pharmaceutical composition which comprises combining a compound of Claim 1 with a pharmaceutically acceptable carrier.

25 27. A method of treating or preventing bone associated pathologies selected from osteosarcoma, osteoarthritis, and rickets which comprises administering a therapeutically effective amount of a compound of Claim 1.

28. The composition of Claim 11 further comprising a second compound selected from:

- 30
- 1) an estrogen receptor modulator,
 - 2) an androgen receptor modulator,
 - 3) retinoid receptor modulator,
 - 4) a cytotoxic agent,
 - 5) an antiproliferative agent,
 - 6) a prenyl-protein transferase inhibitor,
 - 35 7) an HMG-CoA reductase inhibitor,

- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- γ agonist, and
- 12) PPAR- δ agonists.

29. The composition of Claim 28, wherein the second compound is another angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon- α , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.

30. The composition of Claim 28, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

31. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

32. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) PPAR- γ agonists,

- 12) PPAR- δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 16) agent useful in the treatment of neutropenia, and
- 17) an immunologic-enhancing drug.

33. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy and a compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) PPAR- γ agonists,
- 12) PPAR- δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 16) agent useful in the treatment of neutropenia, and
- 17) an immunologic-enhancing drug.

34. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

35. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

36. The method of Claim 35 wherein the GPIIb/IIIa antagonist is tirofiban.

37. A method of reducing or preventing tissue damage following a cerebral ischemic event which comprises administering a therapeutically effective amount of a compound of Claim 1.

5

38. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.